Tradestie Institutional Equity Comparison Engine

EDIT vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EDIT Overall Edge

EDIT Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Editas Medicine, Inc. Common Stock (EDIT) driven by superior Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EDIT N/M vs FDMT N/M Fwd P/E
Growth & Margin Winner EDIT
Op Margin -167.0% vs -222.7% ยท YoY +37.4% vs +4505.6%
Momentum & Technical Winner FDMT
1Y -25.0% vs +13.3% ยท 52W Pos 11% vs 47%
Options & Structure Winner EDIT
BREAKDOWN (38th %ile IV) vs BREAKDOWN (10th %ile IV)
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EDIT -25.0% FDMT +13.33% Spread: +38.33 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EDIT Revenue FDMT Revenue EDIT Op. Margin FDMT Op. Margin Margin Edge
FY2018 $30M N/A -356.1% N/A EDIT
FY2019 $20M $10M -686.4% -729.4% EDIT
FY2020 $90M $10M -148.6% -424.0% EDIT
FY2021 $30M $20M -756.1% -395.5% FDMT
FY2022 $20M $0M -1146.3% -3516.5% EDIT
FY2023 $80M $20M -216.6% -544.6% EDIT
FY2024 $30M $0M -777.2% -507678.4% EDIT
FY2025 $40M $90M -394.9% -187.2% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EDIT (2) vs FDMT (6)
Institutional Metric EDIT FDMT Criterion Row Winner
Market Capitalization Scale $336.5M $669.3M Larger Scale FDMT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +37.4% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability -167.0% -222.7% Higher Margin EDIT
Net Profit Margin Profitability -144.9% -208.6% Higher Margin EDIT
Return on Equity (ROE) Capital Efficiency -147.4% -56.7% Higher ROE FDMT
52-Week Range Position Momentum 11% ($2โ€“$4) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 2.32ฮฒ ยท 102% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk FDMT
Unified Institutional Score Composite Signal 48.4 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EDIT vs FDMT Buy Guide
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EDIT nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.